Clinical Trial Update: Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease. [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating Cabaser (cabergoline) in combination with Sinemet CR for nighttime symptoms in Parkinson's disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Cabaser (cabergoline)
• Sinemet CR (carbidopa/levodopa)

Snippet

Sponsor: Pfizer | Conditions: Parkinson Disease | Phase 4 | Status: TERMINATED